Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4574523 | 0.79 | RAB9A (0.42) | GPR3KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL5483645 | 0.78 | ALDH1A1 (0.55) | GPR3KDM4EALDH1A1HPGDGLA | |
| SCHEMBL31115164 | 0.78 | ALDH1A1 (0.55) | GPR3KDM4EALDH1A1HPGDGLA | |
| SCHEMBL7110614 | 0.78 | ALDH1A1 (0.37) | GPR3KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL1090972 | 0.75 | KDM4E (0.36) | GPR3KDM4EALDH1A1HPGDGLA | |
| SCHEMBL299834 | 0.74 | NPC1 (0.42) | GPR3KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL17048132 | 0.73 | METAP2 (0.41) | GPR3KDM4EALDH1A1RAB9ACYP2A6 | |
| SCHEMBL1725498 | 0.72 | DHODH (0.40) | GPR3 | |
| SCHEMBL5392739 | 0.72 | LMNA (0.46) | GPR3KDM4EALDH1A1HPGDGLA | |
| SCHEMBL7631632 | 0.72 | PIK3CD (0.36) | GPR3ALDH1A1HPGDGLAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714244-B2 | Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors | ALMAC DISCOVERY LIMITED (GB) | 2017-07-25 | — | — | US | disclosed |
| US-9434698-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9345702-B2 | Methods of treatment using selective Bcl-2 inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160106849-A1 | FORMULATIONS OF PHENYL URACIL COMPOUNDS | ABBVIE INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8889675-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2203430-B1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LAB (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011068944-A1 | TETRAIONIC LIQUID SALTS AND METHODS OF USE THEREOF | SIGMA-ALDRICH CO. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110036975-A1 | IMIDAZOLIUM-BASED LIQUID SALTS AND METHODS OF USE THEREOF | SIGMA-ALDRICH CO. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110017908-A1 | DICATIONIC LIQUID SALTS AND METHODS OF USE THEREOF | SIGMA-ALDRICH CO. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2011008915-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011008830-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2008074035-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | WEE1, WEE2, NME1 | GPR3 2861/4885KDM4E 420/4885ALDH1A1 1226/4885 |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | GPR3 4776/4885KDM4E 4649/4885ALDH1A1 2117/4885 |
| US-20160106849-A1 | FORMULATIONS OF PHENYL URACIL COMPOUNDS | UNG, UMPS, TYMP | GPR3 4306/4885KDM4E 1166/4885ALDH1A1 490/4885 |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | GPR3 4428/4885KDM4E 1017/4885ALDH1A1 2908/4885 |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | CDC7, CDK7, CDK17 | GPR3 4339/4885KDM4E 1309/4885ALDH1A1 3421/4885 |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | GPR3 4262/4885KDM4E 2326/4885ALDH1A1 4772/4885 |
| US-20110017908-A1 | DICATIONIC LIQUID SALTS AND METHODS OF USE THEREOF | SRMS, AQP4, SLC6A12 | GPR3 4607/4885KDM4E 3164/4885ALDH1A1 3665/4885 |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | GPR3 3749/4885KDM4E 1090/4885ALDH1A1 2353/4885 |
| US-20110036975-A1 | IMIDAZOLIUM-BASED LIQUID SALTS AND METHODS OF USE THEREOF | SRMS, AQP4, SLC6A12 | GPR3 4583/4885KDM4E 3168/4885ALDH1A1 3524/4885 |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | GPR3 4852/4885KDM4E 3729/4885ALDH1A1 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.